DURECT Announces Positive ELADUR(TM) Phase IIa Stu... ( CUPERTINO Calif. Dec. 18 /- DUREC...)

DURECT Announces Positive ELADUR(TM) Phase IIa Study Results

Date:12/18/2007

CUPERTINO, Calif., Dec. 18 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today positive results from a Phase IIa clinical trial for ELADUR(TM), DURECT's proprietary investigational transdermal pain patch. In this study of patients suffering from post-herpetic neuralgia, ELADUR showed improved pain control versus placebo during the 3-day continuous treatment period. In addition, ELADUR appeared well tolerated overall, and patients treated with ELADUR and placebo exhibited similar safety profiles.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

"To our knowledge, this is the first topical local anesthetic formulation that supports a full 3 days of pain control from a single application," stated James E. Brown, DVM, President and CEO of DURECT. "In this study, ELADUR showed comparable safety to placebo patches as well as good wearability characteristics as patients went about their normal daily activities such as exercising and showering while wearing the patches."

This Phase IIa study was a randomized, multi-center, double-blind, placebo-controlled, two-way cross-over study of 60 patients suffering from post-herpetic neuralgia (post-shingles pain or PHN). The objectives of the study were to assess the safety as well as the magnitude, duration and characteristics of analgesic activity of ELADUR. DURECT anticipates that detailed results will be submitted for presentation at the American Pain Society Annual Meeting in May 2008.

About ELADUR

ELADUR is an investigational transdermal drug patch intended to provide up to 3 days of local pain relief from a single application, as compared to a wea
'/>"/>

SOURCE DURECT Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study

Post Your Comments:

(Date:11/23/2009).../--LightSciencesOncology,Inc.(LSO)todayannouncedth...toanewlycreatedseatonitsboardofdirectors.Mr.Seddig...panies,includingElekta,tomarketleadership. ,, "...thinbusinessdevelopmenttotheboard,"saidLSO,sChairm...ncancer-therapybusinessdevelopment.Hehasoverseenth...

(Date:11/23/2009)...e-FirstCall/-- CumberlandPharmaceuticalsInc. (CPIX...studyevaluatingthesafetyandefficacyofCaldolor( ibu...patients. ,, Statisticalsignificancewasachieved...overthefirst24hoursoftreatment.Thestudyevaluated61...ingmorethan10percenttotalbodysurfacearea.Otherpart...

(Date:11/23/2009)...e-FirstCall/--WoundManagementTechnologies,Inc.,(OT...altymedicalproducts,announcedthatithasfileditQ3200...ementbusinessupdatetoillustratethedevelopmentsduri...33.5%to$102,926vs.Q32008salesof$77,084. , Sha....Q32008shareholderequityof$(321,257) , Totala...

Breaking Medicine Technology:Light Sciences Oncology Elects Akbar Seddigh, Chairman of Elekta AB to Its Board of Directors 2 Caldolor(R) (Ibuprofen) Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients 2 Caldolor(R) (Ibuprofen) Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients 3 Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 2 Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 3 Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 4 Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 5 Outcomes Registry in Heart Attack Patients to Generate Numerous Studies 3B Data Quality Ensured Through Velos Clinical Research Management System 5317 1 Outcomes Registry in Heart Attack Patients to Generate Numerous Studies 3B Data Quality Ensured Through Velos Clinical Research Management System 5317 2 Outcomes Registry in Heart Attack Patients to Generate Numerous Studies 3B Data Quality Ensured Through Velos Clinical Research Management System 5317 3 Outcomes Registry in Heart Attack Patients to Generate Numerous Studies 3B Data Quality Ensured Through Velos Clinical Research Management System 5317 4 Chinese Food and Drug Administration Approves Gabexate Mesylate as Pharmaceutical Raw Material 5315 1 Chinese Food and Drug Administration Approves Gabexate Mesylate as Pharmaceutical Raw Material 5315 2 Survivors of childhood cancer less likely to marry 10291 1 Survivors of childhood cancer less likely to marry 10291 2

[0] Light Sciences Oncology Elects Akbar Seddigh, Chairman of Elekta AB to Its Board of Directors [0] Caldolor(R) (Ibuprofen) Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients [0] Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update

...Data to the NEBIDO NDA PDUFA Date Exp...Jan. 22 Indevus,Pharmaceuticals, Inc. (Nasdaq: I...from its Phase III program for NEBIDO (testosteron...one therapy under development for the,treatment of... has been,filed with the U.S. Food and Drug Admini...

...te Anti-Tumor Activity of Bavituximab in ... TUSTIN, Calif., Jan. 22 Peregrine,Pharmaceutical...maceutical,company developing monoclonal antibodie...s (HCV) infection, today announced that its Phase ...nation with chemotherapy in,patients with non-smal...

Other Medicine Technology:Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R) 2 Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R) 3 Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R) 4 Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R) 5 Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R) 6 Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer 2 Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer 3 Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer 4

Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer

(Date:11/24/2009)... , Health Care Reform cre...mdash;such as managing chronic care treatment&mdas...t. , Alpharetta, GA (Vocu...oncerning health care reform is controversial, to ...surers, legislators and policy makers all weighing...

(Date:11/24/2009)... , Slate and New Markets ...he business services sector. , ...Slate Capital Group ( www.slatecap.com ), a privat...w Markets Venture Partners ( www.newmarketsvp.com ...aryland, today announced that they have acquired E...

(Date:11/24/2009)... , Two expert therapists ...ink readers. a - ban,- don: verb: to leave comple... Vancouver, Canada (Vocus) N...role Gaato today announced the second webinar is i...Century Therapy" series from MyShrink.com ( h...

(Date:11/24/2009)... , Sinusitis patients lif...nic sinusitis, Sinus Dynamics non-invasive nasal s...venience of treating all types of Sinusitis withou...ny sinus surgery. Researchers found 82.9% of patie...ized antibiotics with mean particle diameter of 3....

(Date:11/24/2009)... , NCL Security Launches ...Industry to Generate Recurring Monthly Revenue for... Dallas, Texas (PRWEB) November 24...Video Platform for the Security Industry to Genera...and Security Dealers., , ,"Integrated securit...

Breaking Medicine News(10 mins):Health News:Jackson & Coker Industry Report Addresses Health Care Reform 2 Health News:Jackson & Coker Industry Report Addresses Health Care Reform 3 Health News:Slate Capital Group and New Markets Venture Partners Acquire eCoast Sales Solutions 2 Health News:Slate Capital Group and New Markets Venture Partners Acquire eCoast Sales Solutions 3 Health News:Home For the Holidays: MyShrink.com Announces the Second in its Successful Six-Part Webinar Series: "Abandonment: The Hidden Fear" 2 Health News:Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery 2 Health News:Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery 3 Health News:Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery 4 Health News:NCL Security Launches EyeCentral Video Platform for the Security Industry to Generate Recurring Monthly Revenue for Central Stations and Security Dealers 2

[0] Jackson & Coker Industry Report Addresses Health Care Reform [0] Slate Capital Group and New Markets Venture Partners Acquire eCoast Sales Solutions [0] Home For the Holidays: MyShrink.com Announces the Second in its Successful Six-Part Webinar Series: "Abandonment: The Hidden Fear"[0] Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery [0] NCL Security Launches EyeCentral Video Platform for the Security Industry to Generate Recurring Monthly Revenue for Central Stations and Security Dealers

...3.9 Million; 29% Increase .... Sales of $2.2 Million; 83% Increase ...linical Study Launched to Expand Reimbursement, Su...c. (Amex:,UPI), a medical device company that deve...

...rs, Joe Torre; and Cedars-Sinai, Medical Center, ... Wyman Humanitarian Award at Awards Gala on We... Southern California,Chapter of the Arthritis Foun...lls hotel. The highlight of the evening will,be th...

...o save $7 billion in related health-care costs , ...ccinating infants with what,s known as the "7 vale...ve more than 357,000 lives and $7 billion in costs...h as meningitis) and other bacterial infections ca...

... Recognizing the nationwide critical need for tech... by accurately tracking their location inside buil...rded Worcester Polytechnic Institute (WPI) $430,00...go. It was also announced that, with this funding,...

...re,s Global Promise, DALLAS, Oct. 29 Susan G. Ko...st cancer movement, is expanding its international...vice president of,international, reporting to Kome...t, implementation and management of,Komen,s growin...

...hoose Regence,s,Health Savings Account (HSA) will ...e company has added U.S. Bank as a banking partner... approach to health care banking,and its strong co...evel of quality and,financial services they have c...

Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 Arthritis Foundation Honors Comerica Bank at 'Commitment To A Cure' Awards Gala Flu Vaccine Could Prevent 357,000 Deaths in Pandemic WPI receives award from Homeland Security Department to advance first-responder location Susan G. Komen for the Cure(R) Strengthens Global Mission With Addition of Vice President, International Regence Teams With U.S. Bank to Offer New Health Savings Account Solution

The Natural-Hip Family - Revision/Trauma Nonporous CoCr

MARATHON Cross Linked Polyethylene Acetabular Liner

Ringloc Acetabular Liners

Olympia Total Shoulder System

Medicine Products:

The Natural-Hip Family - Revision/Trauma Nonporous CoCr MARATHON Cross Linked Polyethylene Acetabular Liner Ringloc Acetabular Liners Olympia Total Shoulder System

DURECT Announces Positive ELADUR(TM) Phase IIa Stu...( CUPERTINO Calif. Dec. 18 /- DUREC...),Health